Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

1436P - Better overall survival of male versus female patients with advanced gastric adenocarcinoma

Date

14 Sep 2024

Session

Poster session 18

Topics

Cancer Biology;  Cancer Diagnostics;  Genetic Testing and Counselling;  Cancer Research

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Minggui Pan

Citation

Annals of Oncology (2024) 35 (suppl_2): S878-S912. 10.1016/annonc/annonc1603

Authors

M. Pan1, J. Stover2, A. Dang2, M. Tong2, T. Huang2, C. Jiang3, J. Bien3, L. Habel4, S.P. Thomas5, A. Pinto2, E. Chung2, N. Achacoso@kp.org2, P. Tse2

Author affiliations

  • 1 900 Blake Wilbur Dr, Stanford University, 94305–2004 - Stanford/US
  • 2 Internal Medicine, Kaiser Permanente Santa Clara Medical Center and Medical Offices, 95051 - Santa Clara/US
  • 3 Hematology/oncology, Kaiser Permanente Santa Clara Medical Center and Medical Offices, 95051 - Santa Clara/US
  • 4 Research Department, Kaiser Permanente Santa Clara Medical Center and Medical Offices, 95051 - Santa Clara/US
  • 5 Hematology Oncology, Kaiser Permanente Vallejo Medical Center, 94589 - Vallejo/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1436P

Background

To understand if there is sex disparity in survival outcomes among the patients with advanced gastric adenocarcinoma (GAC), gastroesophageal junction adenocarcinoma (GEJAC), and esophageal adenocarcinoma (EAC).

Methods

The study included patients from Kaiser Permanente Northern California with metastatic or relapsed EAC, GEJAC and GAC whose tumor underwent next-generation sequencing. We used Cox regression modeling to examine association of male and female patients with overall survival (OS) adjusting for demographics, performance status, Charlson comorbidity index, receipt of chemotherapy, and six most common genomic alterations including HER2 overexpression/amplification, p53, KRAS, CDKN2A, PIK3CA co-mutation and Myc amplification.

Results

Among 875 eligible patients, 275 were female and 600 were male. OS for male versus female patients did not appear substantially different for the entire cohort (HR = 0.87; [95% CI, 0.74-1.03]), for EAC (HR = 1.0; [95% CI, 0.57-1.74]) and GEJAC (HR = 1.14; (95% CI, 0.77-1.67]) subgroups. However, OS of male versus female patients with GAC appeared substantially better (HR = 0.75; [95% CI, 0.60-0.93]). In addition, this substantial OS difference was preserved regardless of HER2 status, CDKN2A and PIK3CA mutation or Myc amplification. Intriguingly, despite overall there was no OS difference between male versus female GAC patients regardless of p53 mutation status, however, among GAC patients with a p53 mutation, male had substantially better OS than female patients only if tumor carried non-gain-of-function (non-GOF, HR = 0.59; [95% CI, 0.41-0.85]) but not gain-of-function mutation (GOF, HR = 1.46; [95% CI, 0.74-2.87]).

Conclusions

We have found that male versus female GAC patients had substantially better overall survival. Most intriguingly, the survival difference among patients with mutp53 was only observed if tumor carried mutp53 non-GOF. Our results for the first time identified a sex disparity in survival outcomes that is associated with a common molecular lesion and can have important implications in understanding the biology of GAC and in clinical practice for prognostic stratification.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.